Business
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category of antivirals engineered to target shared viral mechanisms using its proprietary peptide conjugate platform, IMP3ACT™, today announced that members of its executive leadership will present across two leading peptide therapeutics conferences in Boston the week of April 27, 2026.
About this update from Decoy Therapeutics Inc.
[{"type":"text","content":"CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design ","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp to Co-Present at Peptide-Based Therapeutics Summit; Advisor Dr. Bradley Pentelute to Deliver Opening Remarks","length":156,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., April 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category of antivirals engineered to target shared viral mechanisms using its proprietary peptide conjugate platform, IMP3ACT™, today announced that members of its executive leadership will present across two leading peptide therapeutics conferences in Boston the week of April 27, 2026.","length":475,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":104,"url":"https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YyEL5SG8p3qov4E54_d53A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4Mw--/https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a","width":400,"height":104}},"href":"https://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"At the Oligonucleotide & Peptides HubXchange on April 30, Chief Business Officer Peter Marschel will lead a 60-minute roundtable discussion titled "Key challenges in computational design of peptide therapeutics: From natural ligand reengineering to de novo design." The session will examine how generative design approaches have the potential to move peptide discovery beyond the traditional evolutionary sampling that shaped therapeutics such as GLP-1 agonists, toward de novo design of peptide drugs against novel targets.","length":538,"tagName":"p"},{"type":"text","content":"The company recently announced a strategic partnership with Quantori to deploy a Google Cloud-native, AI-driven peptide design and molecular simulation platform, shortening the cycle from peptide design to D-...